Healthcare Industry News:  IGRT 

Devices Oncology

 News Release - May 31, 2006

Varian Medical Systems Equipment Selected for Wave 9 of UK Cancer Plan

CRAWLEY, England, May 31 (HSMN NewsFeed) -- Varian Medical Systems, world leader in radiotherapy systems for treating cancer, has been selected to supply several hospitals with treatment machines and simulators in the latest wave of the UK government's capital investment program for upgrading the quality of cancer treatments in the nation's hospitals.

The latest Varian Clinac(R) iX series accelerators -- machines that deliver radiotherapy -- will be installed at leading radiotherapy centers in Royal Free (London), Ipswich and Maidstone in Wave 9 of the Cancer Plan. These machines will be equipped with the On-Board Imager(R) accessory to enable the hospitals to carry out more targeted treatments using Image Guided Radiotherapy (IGRT). Additionally Varian will be equipping an entirely new radiotherapy center at Chelmsford in Essex with a complete suite of Varian's radiotherapy products including a Clinac iX, the ARIA(TM) information and image management system and Eclipse(TM) treatment planning software.

Also as part of Wave 9, Varian's Acuity(TM) X-ray imaging device for simulating, verifying and planning radiotherapy treatments will be installed at centers in Mount Vernon (London), Exeter, Carlisle, Lincoln and Stoke. Manufactured in Crawley, England and installed in over 30 countries worldwide, the Acuity system generates high-quality digital images to support all forms of radiotherapy, including state-of-the-art treatments such as IGRT. The Acuity device can also be used with Varian's unique respiratory gating system to plan more precise treatments in which beam delivery times are coordinated with tumor motion caused by patients' natural breathing cycles. At Carlisle, Varian will also be supplying brachytherapy equipment that enables clinicians to place radiation sources such as seeds directly within tumors.

Over the last three years, the UK government's Purchasing and Supply Agency (PASA) has announced major investments in radiotherapy equipment in a series of waves. A total of 101 new linear accelerators have been acquired as part of the Cancer Plan and Varian has been selected to provide 65 of them -- two-thirds of all machines ordered.

"We already have a Varian linear accelerator and our people have been very happy with its performance and reliability, and matching and integrating our existing equipment is an important factor for us," says Stephen Duck, head of radiation physics at London's Royal Free Hospital. "We're very keen to introduce image-guided treatments and we feel the On-Board Imager is an exciting step forward for our staff and our patients."

Once the new machines are installed, the oncology department at Royal Free Hospital plans to begin developing treatments using intensity modulated radiation therapy (IMRT), a new treatment that enables clinicians to increase doses delivered to the tumor while protecting surrounding healthy tissues. The new treatment machines will be equipped to provide state-of-the-art care with 120-leaf multileaf collimators -- digital devices that shape the beam of radiation to conform to the contours of the tumor. They will also have the latest in portal imaging technology for helping to ensure that treatments are delivered accurately.

David Scott, Varian's UK sales manager, says, "This latest wave of the government's Capital Investment Programme demonstrates again that the UK radiotherapy community recognises Varian's reliability and long term development strategy as well as our ability to deliver practical leading edge technology to enable the adoption of advanced techniques such as IMRT, IGRT and Adaptive Radiotherapy in today's high pressure clinical environment."

Editorial contact: Neil Madle, Varian Medical Systems, +44 7786 526068, neil.madle@varian.com

About Varian Medical Systems

Varian Medical Systems, Inc., of Palo Alto, California is the world's leading manufacturer of medical technology for treating cancer with radiotherapy and neurological conditions with radiosurgery. The company is also a premier supplier of X-ray tubes and flat-panel digital subsystems for imaging in medical, scientific, and industrial applications. Varian Medical Systems employs approximately 3,600 people who are located at manufacturing sites in North America and Europe and in its 56 sales and support offices around the world. In Europe, the company operates manufacturing and engineering centers in Baden (Switzerland), Crawley (England), Haan (Germany), Helsinki (Finland) and Toulouse (France) and has headquarters for Europe, Middle East, India and Africa (EMEA) based in Zug, Switzerland.

Additional information is available on the company's web site at http://www.varian.com/

Forward Looking Statements

Statements in this press release regarding future business, events, plans, objectives, expectations, estimates, and other similar matters, including, but not limited to, statements using the terms "can" and "expect," constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements contained in this press release are subject to risks and uncertainties that could cause actual results to differ materially from those anticipated, including, but not limited to, the risks described in the company's Annual Report on Form 10-K and other reports filed from time to time by the Company with the Securities and Exchange Commission. These forward-looking statements represent the Company's judgment as of the date of this press release. The Company assumes no obligation to update or revise these forward-looking statements because of new information, future events, or otherwise.


Source: Varian Medical Systems

Issuer of this News Release is solely responsible for its content.
Please address inquiries directly to the issuing company.



FindReps 2 - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps 2 - available on the Apple App Store for iPhone and iPad.